Search

Your search keyword '"Iluvien (Medication)"' showing total 516 results
Start Over Descriptor "Iluvien (Medication)"
516 results on '"Iluvien (Medication)"'

151. Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

Subjects
Vice presidents (Organizations) -- Appointments, resignations and dismissals, Medical societies, Fluocinolone, Retinal diseases, Ophthalmology, Diseases, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, March 31, Mar 31, 2020 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management [...]

Published
2020

155. Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement

Subjects
United States. Securities and Exchange Commission, Fluocinolone, Retinal diseases, Diseases, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Feb 24, 2020 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in the commercialization and development of prescription ophthalmology treatments for the management of [...]

Published
2020

156. Alimera Sciences Refinances Its Debt Facility With Solar Capital

Subjects
Syndicated loans, Fluocinolone, Fees, Retinal diseases, Legal fees, Ophthalmology, Company financing, Petroleum, energy and mining industries, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that it refinanced [...]

Published
2020

157. Alimera Sciences Refinances Its Debt Facility with Solar Capital

Subjects
Iluvien (Medication)
Abstract

ENPNewswire-January 7, 2020--Alimera Sciences Refinances Its Debt Facility with Solar Capital (C)2020 ENPublishing - http://www.enpublishing.co.uk Release date- 06012020 - ATLANTA - Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in [...]

Published
2020

158. Alimera Sciences Refinances Its Debt Facility With Solar Capital

Subjects
Syndicated loans, Fluocinolone, Fees, Retinal diseases, Legal fees, Ophthalmology, Company financing, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that it refinanced [...]

Published
2020

159. Alimera Sciences Refinances Its Debt Facility With Solar Capital

Subjects
Syndicated loans, Fluocinolone, Retinal diseases, Ophthalmology, Company financing, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Jan 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- -- Three-year interest-only period -- Additional $2.5 million available under certain conditions Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in [...]

Published
2020

161. Q2 2018 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, European Union, Iluvien (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to Alimera Sciences Second Quarter 2018 Results Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the [...]

Published
2018

162. Q1 2018 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to the Alimera Sciences' First Quarter 2018 Results Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn [...]

Published
2018

163. Q4 2017 Knight Therapeutics Inc Earnings Call - Final

Subjects
Patient compliance, Business, Movantik (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. My name is Jessa, and I will be your operator today. Welcome to Knight Therapeutics Inc. 2017 Fourth Quarter and Year End Financial [...]

Published
2018

164. Q4 2017 Knight Therapeutics Inc Earnings Call - Final

Subjects
Patient compliance, Business, Movantik (Medication), Iluvien (Medication)
Abstract

Presentation OPERATOR: Good morning, ladies and gentlemen. My name is Jessa, and I will be your operator today. Welcome to Knight Therapeutics Inc. 2017 Fourth Quarter and Year End Financial [...]

Published
2018

165. Q4 2017 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to the Alimera Sciences' Fourth Quarter and Year-end 2017 Earnings Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now [...]

Published
2018

166. Alimera Sciences Issues ILUVIEN Data at 2016 ARVO

Subjects
Vascular endothelial growth factor, Ophthalmology, Arts and entertainment industries, Iluvien (Medication)
Abstract

Alimera Sciences reported that data from seven ILUVIEN post marketing studies were presented during the 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) in Seattle, [...]

Published
2016

167. Q2 2017 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to the Alimera Sciences' Second Quarter 2017 Update Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn [...]

Published
2017

168. Q1 2017 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Greetings, and welcome to the Alimera Sciences First Quarter 2017 Results Call. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn [...]

Published
2017

169. Alimera Sciences Inc at ROTH Conference - Final

Subjects
Novartis Ophthalmics -- Conferences, meetings and seminars, Ophthalmology -- Conferences, meetings and seminars, Business, Iluvien (Medication)
Abstract

Presentation SCOTT HENRY, ANALYST, ROTH CAPITAL PARTNERS: Okay, we are going to move on to our next presentation from Alimera Sciences, ticker ALIM, an approximately $125 million market cap company [...]

Published
2017

170. Alimera Sciences Inc at Cowen Health Care Conference - Final

Subjects
Health care industry -- Conferences, meetings and seminars, Health care industry, Business, Iluvien (Medication)
Abstract

Presentation UNIDENTIFIED ANALYST: Good afternoon. Welcome to the Cowen and Company 37th annual healthcare conference. We have with us today, Dan Myers, CEO of Alimera Sciences. DAN MYERS, CEO, ALIMERA [...]

Published
2017

171. Q4 2016 Alimera Sciences Inc Earnings Call - Final

Subjects
Business, Iluvien (Medication)
Abstract

Presentation OPERATOR: Greetings and welcome to the Alimera Sciences fourth quarter 2016 results call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow [...]

Published
2017

173. EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU Within One of the Largest Integrated Delivery Systems in the U.S

Subjects
Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

ENPNewswire-December 5, 2019--EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU Within One of the Largest Integrated Delivery Systems in the U.S. (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 04122019 [...]

Published
2019

174. EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU Within One of the Largest Integrated Delivery Systems in the U.S

Subjects
Fluocinolone, Distribution channels, Business, international, Law, Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

(GlobeNewswire) - EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has entered into a formal two-year contract [...]

Published
2019

175. Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

Subjects
Fluocinolone, Retinal diseases, Media executives, Ophthalmology, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Dec 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera' or 'Company'), a leader in the commercialization and development of prescription ophthalmology treatments for the [...]

Published
2019

176. Alimera Announces Regulatory Approval for ILUVIEN in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Subjects
Recurrence (Disease) -- Care and treatment, Fluocinolone, Uveitis -- Care and treatment, Government agencies, Medical supplies, Retinal diseases, Marketing, Ophthalmology, Business, international, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the governmental agencies [...]

Published
2019

177. EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU(R) Within One of the Largest Integrated Delivery Systems in the U.S

Subjects
Fluocinolone, Distribution channels, Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

WATERTOWN, Mass., Dec 04, 2019 (GLOBE NEWSWIRE via COMTEX) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that [...]

Published
2019

179. Alimera Announces Regulatory Approval for ILUVIEN in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Subjects
Recurrence (Disease) -- Care and treatment, Fluocinolone, Uveitis -- Care and treatment, Government agencies, Medical supplies, Retinal diseases, Marketing, Ophthalmology, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the governmental agencies [...]

Published
2019

180. Alimera Announces Regulatory Approval for ILUVIEN(R) in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Subjects
Recurrence (Disease) -- Care and treatment, Fluocinolone, Uveitis -- Care and treatment, Medical supplies, Retinal diseases, Marketing, Ophthalmology, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Dec 03, 2019 (GLOBE NEWSWIRE via COMTEX) -- Company continues to execute on its international expansion strategy Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in the commercialization and [...]

Published
2019

182. Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

Subjects
Conferences and conventions -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Retinal diseases, Media executives, Ophthalmology, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Nov 26, 2019 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera' or 'Company'), a leader in the commercialization and development of prescription ophthalmology treatments for the [...]

Published
2019

183. EyePoint Pharmaceuticals Announces Amendment to CRG Debt Facility

Subjects
Syndicated loans, Fluocinolone, Backup software, Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

WATERTOWN, Mass., Nov 19, 2019 (GLOBE NEWSWIRE via COMTEX) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced an amendment [...]

Published
2019

184. Alimera Sciences Terminates Equity Purchase Agreement

Subjects
Fluocinolone, Retinal diseases, Banking, finance and accounting industries, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has terminated [...]

Published
2019

185. EyePoint Pharmaceuticals Appoints George O. Elston as Chief Financial Officer and Head of Corporate Development

Subjects
Fluocinolone, Consultants (Persons), Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

WATERTOWN, Mass., Nov 14, 2019 (GLOBE NEWSWIRE via COMTEX) -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the appointment [...]

Published
2019

186. Alimera Sciences Terminates Equity Purchase Agreement

Subjects
Iluvien (Medication)
Abstract

ENPNewswire-November 14, 2019--Alimera Sciences Terminates Equity Purchase Agreement (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 13112019 - ATLANTA - Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in the commercialization and [...]

Published
2019

187. Alimera Sciences Terminates Equity Purchase Agreement

Subjects
Fluocinolone, Retinal diseases, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Nov 13, 2019 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in the commercialization and development of prescription ophthalmology treatments for the management of [...]

Published
2019

190. Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

Subjects
Sheraton New York Times Square Hotel -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Hotels and motels -- Conferences, meetings and seminars -- United States, Fluocinolone -- Conferences, meetings and seminars, Chief financial officers -- Conferences, meetings and seminars, Retinal diseases, Media executives, Ophthalmology, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Nov 05, 2019 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera' or 'Company'), a leader in the commercialization and development of prescription ophthalmology treatments for the [...]

Published
2019

193. EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU

Subjects
Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

ENPNewswire-November 4, 2019--EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU (C)2019 ENPublishing - http://www.enpublishing.co.uk Release date- 01112019 - WATERTOWN - EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a [...]

Published
2019

194. EyePoint Pharmaceuticals Secures New Patient Access Agreement with Vizient Inc. for DEXYCU(R)

Subjects
Fluocinolone, Medical schools, Management consultants, Medical centers, Ambulatory care, Banking, finance and accounting industries, Business, Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

WATERTOWN, Mass., Nov 01, 2019 (GLOBE NEWSWIRE via COMTEX) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that [...]

Published
2019

198. Alimera Obtains Marketing Authorization for ILUVIEN(r) in Portugal for the Treatment of Non-Infectious Posterior Uveitis

Subjects
Marketing, Uveitis, Edema, Medical supplies, Retinal diseases, Physicians, Recurrence (Disease), Ophthalmology, General interest, News, opinion and commentary, Iluvien (Medication)
Abstract

ATLANTA: Alimera Sciences, Inc. has issued the following press release: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in the commercialization and development of prescription ophthalmology treatments for the management [...]

Published
2019

200. Alimera Obtains Marketing Authorization for ILUVIEN(R) in Portugal for the Treatment of Non-Infectious Posterior Uveitis

Subjects
Recurrence (Disease), Marketing, Fluocinolone, Uveitis, Edema, Medical supplies, Retinal diseases, Ophthalmology, Banking, finance and accounting industries, Business, Iluvien (Medication)
Abstract

ATLANTA, Oct 03, 2019 (GLOBE NEWSWIRE via COMTEX) -- Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a leader in the commercialization and development of prescription ophthalmology treatments for the management of [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results